Opportunity
Federal Register #2026-08791
Exclusive Patent License for Engineered TCR Cell Therapies for Cancer (NIH/NCI)
Buyer
Department of Health and Human Services, National Institutes of Health
Posted
May 06, 2026
Respond By
May 21, 2026
Identifier
2026-08791
NAICS
541714, 533110
This opportunity involves the potential grant of an exclusive patent license by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for advanced cell therapy technologies: - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services - OEM/Vendor: - OncoVanta Therapeutics, Inc. (prospective licensee) - Products/Technologies: - Intellectual property covering engineered T Cell Receptor (TCR) therapies targeting mutated forms of tumor protein p53 for cancer treatment - Patent family includes U.S., PCT, Canadian, Japanese, European, South Korean, Australian, Chinese, and Hong Kong filings - Scope and Requirements: - License is exclusive and limited to TCR-engineered T cell therapy products for human cancer treatment - Opportunity is for development and commercialization of these therapies - No physical products, part numbers, or purchase quantities specified; this is a licensing opportunity for intellectual property rights - Interested parties may submit comments or license applications to the NCI Technology Transfer Center - Notable Details: - The license is for a specific field of use: TCR-engineered cell therapies for cancer - The underlying inventions are assigned to the U.S. Government - Locations: - National Cancer Institute, NIH offices and facilities in Bethesda, MD
Description
The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, is considering granting an exclusive patent license to OncoVanta Therapeutics, Inc. The license pertains to inventions related to engineered T Cell Receptor therapies targeting mutated forms of tumor protein p53 for cancer treatment. The license aims to facilitate development and commercialization of these engineered cell therapies. Written comments or license applications must be received by May 21, 2026.